Suwala, Abigail K.
Felix, Marius
Friedel, Dennis
Stichel, Damian
Schrimpf, Daniel
Hinz, Felix
Hewer, Ekkehard
Schweizer, Leonille
Dohmen, Hildegard
Pohl, Ute
Staszewski, Ori
Korshunov, Andrey
Stein, Marco
Wongsurawat, Thidathip
Cheunsuacchon, Pornsuk
Sathornsumetee, Sith
Koelsche, Christian
Turner, Clinton
Le Rhun, Emilie
Mühlebner, Angelika
Schucht, Philippe
Özduman, Koray
Ono, Takahiro
Shimizu, Hiroaki
Prinz, Marco
Acker, Till
Herold-Mende, Christel
Kessler, Tobias
Wick, Wolfgang
Capper, David
Wesseling, Pieter
Sahm, Felix
von Deimling, Andreas
Hartmann, Christian
Reuss, David E. http://orcid.org/0000-0002-4573-6033
Funding for this research was provided by:
deutsche forschungsgemeinschaft (404521405, 404521405)
bundesministerium für bildung und forschung (031L0212A)
deutsche krebshilfe (70112188)
niedersächsischen krebsgesellschaft
Universitätsklinikum Heidelberg
Article History
Received: 30 July 2021
Revised: 15 November 2021
Accepted: 5 December 2021
First Online: 30 December 2021
Declarations
:
: Under a licensing agreement between DIANOVA GmbH, Hamburg, Germany, and the German Cancer Research Center, DC, CH, AVD are entitled to a share of royalties received by the German Cancer Research Center on the sales of H09 antibody. The terms of this arrangement are being managed by the German Cancer Research Center in accordance with its conflict of interest policies. AVD and DER have licensed the NFC antibody to Merck Millipore. All terms are being managed by the University of Heidelberg in accordance with its conflict of interest policies.